Bayer/Onyx Nexavar Extends Life In Rare Thyroid Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory filings will be based on results of the Phase III DECISION trial reported at ASCO showing a near double progression-free survival advantage compared to placebo; no further overall survival analyses will be done because of crossover.